2023 (26 POSTS)
Pastula S , Suh M , Jiang X , Reichert H , Movva N , Fryzek J, Simões EAF. Respiratory syncytial virus (RSV) and bronchiolitis epidemiology among the United States infant Medicaid populations in seven states. Poster 191, International Society for Pharmacoepidemiology (ICPE) Annual Meeting, Halifax, Nova Scotia, August 2023.
View Abstract
Publication: Abstracts and Presentations
Bonkowsky J, Healey B, Sacks NC , McLin R, Cyr PL , Sawyer EK, Stephen CD, Eichler F. Point of care analysis for men with adrenomyeloneuropathy: A retrospective study of real world data. Poster presentation, European Academy of Neurology, Budapest, Hungary, July 2023.
Publication: Abstracts and Presentations
Seo S, Healey B, McLin R, Sacks N , Benson C, Citrome L. Health disparities among patients with schizophrenia in an integrated healthcare system. Poster presentation, Psych Congress Elevate 2023, May 30-June 2, 2023.
Publication: Abstracts and Presentations
Bean K, Miller B , Jensen I , Fields C, Pang F. Evaluating the face validity of health state utility values (HSUVS) for metachromatic leukodystrophy (MLD). Abstract EE285 , ISPOR 2023.
View Abstract
Publication: Abstracts and Presentations
Jensen I , Srivastava K, Minshall M, Kemp R. Estimating the lifetime burden of illness in patients with bronchiolitis obliterans syndrome. Abstract EE539 , ISPOR 2023, Boston, MA, May 2023.
View Abstract
Publication: Abstracts and Presentations
Bean K, Olaye A, Miller B , Jensen I , Dean R, Pang F. Direct cost analysis associated with the management of patients with metachromatic leukodystrophy (MLD) across nine European countries. Abstract EE408 , ISPOR 2023, Boston, MA, May 2023.
View Abstract
Publication: Abstracts and Presentations
Bonkowsky J, Healey B, Sacks NC , McLin R, Cyr P , Sawyer E, Stephen CD, Eichler F. Healthcare utilization, burden of illness, and mortality in adults with adrenomyeloneuropathy: The case for genetic therapies. Poster presentation, American Society of Cell and Gene Therapy Meeting, Los Angeles, CA, May 2023.
Publication: Abstracts and Presentations
Bonkowsky J, Healey B, Sacks NC , McLin R, Cyr P , Sawyer E, Stephen CD, Eichler F. Substantial burden of illness and mortality in men with adrenomyeloneuropathy. Poster presentation at American Academy of Neurology Annual Meeting, April 2023.
Publication: Abstracts and Presentations
Minshall M, Emden M, McLin R, Kemp P, Pontenani F, Cardosi L, Sacks N . The cost of non-cystic fibrosis bronchiectasis (NCFB) in patients with commercial insurance or Medicare coverage in the US. Poster presentation, ISPOR, April 2023.
Publication: Abstracts and Presentations
Eichler F, Bonkowsky J, Healey B, Sacks NC , McLin R, Cyr P , Sawyer E, Stephen C. The economic impact of adrenomyeloneuropathy (AMN) on direct medical costs in commercially insured US adults: A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.
Publication: Abstracts and Presentations
Bonkowsky J, Healey B, Sacks NC , McLin R, Cyr P , Sawyer E, Stephen C. Hospitalizations, clinical characteristics and mortality in adults with adrenomyeloneuropathy (AMN): A retrospective study. Poster presentation, ISPOR 27th International Meeting, Boston, MA, April 2023.
Publication: Abstracts and Presentations
Suh M, Reichert H, Jiang X, Pastula ST, Movva N, Fryzek J, Simoes E. The burden of RSV and bronchiolitis in the US infant Medicaid population extends beyond the inpatient setting. Oral presentation to the Pediatric Academic Societies Meeting, Washington, DC, April 2023.
Publication: Abstracts and Presentations
Pang F, Dean R, Jensen I , Bean K, Fields C, Miller B . 2023. The cost-effectiveness of OTL-200 for the treatment of metachromatic leukodystrophy (MLD) in the US. Mol Gene Metab 138(2):107258; doi: 10.1016/j.ymgme.2022.107258 .
Publication: Abstracts and Presentations
Bullano M, Cool C, Schultz BG, Durgapal S, Sacks N , Liu Y , Kee R, Batt K. 2023. Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert Rev Phamacoecon Outcomes Res 23(2):225-230; doi: 10.1080/14737167.2023.2160705 . PMID: 36537696.
View Abstract
Publication: Manuscripts
2022 (16 POSTS)
Broome CM, Hooda N , Su J, Jiang X , Nicholson G, Frankenfeld CL , Iglesias-Rodriguez M, Fryzek J, Patel Parija. 2022. Medically-attended anxiety and depression is increased among newly diagnosed patients with cold agglutinin disease: Analysis of an integrated claim-clinical cohort in the United States. PLoS One 17(12):e0276617; doi: 10.1371/journal.pone.0276617 . PMID: 36520848.
View Abstract
Publication: Manuscripts
Leslie TF, Frankenfeld CL , Menon N. 2022. Disparities in colorectal cancer time-to-treatment and survival time associated with racial and economic residential segregation surrounding the diagnostic hospital, Georgia 2010–2015. Cancer Epidemiol 81(Dec):102267; doi: 10.1016/j.canep.2022.102267 . PMID: 36166941.
View Abstract
Publication: Manuscripts
Sheshadri A, Sacks NC , Healey B, Cyr P , Boerner G, Huang HJ. 2022. The healthcare resource utilization and costs of chronic lung allograft dysfunction following lung transplantation in patients with commercial insurance in the United States. J Med Econ 25(1):650–659; doi: 10.1080/13696998.2022.2071065 . PMID: 35502563.
View Abstract
Publication: Manuscripts
Cardosi L, Rau R, Emdem MR, Kemp R, Minshall M, Pontenani F, Provision S, Sacks N . 2022. Healthcare resource utilization in non-cystic fibrosis bronchiectasis (NCFB) patients with commercial insurance coverage in the US. Value in Health 25(12):S89-S90; doi: 10.1016/j.jval.2022.09.437 .
View Abstract
Publication: Manuscripts
Jensen I , Cyr P . 2022. Early health economic models in gene and cell therapy to inform clinical trial design and optimize commercialization efforts. White Paper. PharmaLive .
Publication: White paper
Yao W, Jensen I , Claussen M, Dandurand K, Buffington B, Fuentes D, Mikhael M. 2022. Health economics of selective early rescue surfactant administration and standard surfactant administration for newborns with respiratory distress syndrome. J Pediatr Pharmacol Ther 27(8):695–702; doi: 10.5863/1551-6776-27.8.695 . PMID: 36415764.
View Abstract